Trial · NCT06899594
Registered outcomes40
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 40
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Participant retention rate | Screening, Visit #1 | Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant). |
| Primary | Participant retention rate | Baseline Assessments, Visit #2 | Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant). |
| Primary | Participant retention rate | Preparatory Session #1, Visit #3 (on study day (-)14; 14 days prior to dosing) | Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant). |
| Primary | Participant retention rate | Preparatory Session #2, Visit #4 (on study day (-) 7; 7 days prior to dosing) | Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant). |
| Primary | Participant retention rate | Preparatory Session #3, Visit #5 (on study day (-)3; 3 days prior to dosing) | Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant). |
| Primary | Participant retention rate | Day of drug administration, Visit #6 (on study day 0) | Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant). |
| Primary | Participant retention rate | 1-Day post drug administration integration session, Visit #7 | Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant). |
| Primary | Participant retention rate | 7-Day post drug administration integration session, Visit #8 | Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant). |
| Primary | Participant retention rate | 30-days post drug administration follow-up (Follow-up #1), Visit #9 | Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant). |
| Primary | Participant retention rate | 60-days post drug administration follow-up (Follow-up #2), Visit #10 | Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant). |
| Primary | Participant retention rate | 120-days post drug administration follow-up (Follow-up #3), Visit #11 (Final visit) | Description: Retention in the study will be assessed by measuring the percentage of study visits completed per participant. Measure: * Retention rate (percent of scheduled study visits completed by each participant). |
| Primary | Preliminary efficacy of psilocybin on methamphetamine abstinence | Screening, Visit #1 | Description: Methamphetamine abstinence will be assessed using both objective and self-reported substance use measures. Measure: * Urine drug screen results (positive/negative for methamphetamine). |
| Primary | Preliminary efficacy of psilocybin on methamphetamine abstinence | Day of drug administration, Visit #6 (on study day 0) | Description: Methamphetamine abstinence will be assessed using both objective and self-reported substance use measures. Measure: * Urine drug screen results (positive/negative for methamphetamine). |
| Primary | Preliminary efficacy of psilocybin on methamphetamine abstinence | 120 days post drug administration (Follow up #3), Visit #11(final visit) | Description: Methamphetamine abstinence will be assessed using both objective and self-reported substance use measures. Measure: * Urine drug screen results (positive/negative for methamphetamine). |
| Primary | Preliminary efficacy of psilocybin on methamphetamine abstinence | Screening, Visit #1 | Description: Methamphetamine abstinence will be assessed using both objective and self-reported substance use measures. Measure: * Timeline Followback (TLFB): Self-reported days of methamphetamine use in the past 30 days. |
| Primary | Preliminary efficacy of psilocybin on methamphetamine abstinence | 30 day post drug administration (Follow up #1), Visit #9 | Description: Methamphetamine abstinence will be assessed using both objective and self-reported substance use measures. Measure: * Timeline Followback (TLFB): Self-reported days of methamphetamine use in the past 30 days. |
| Primary | Preliminary efficacy of psilocybin on methamphetamine abstinence | 60 day post drug administration (Follow up #2), visit #10 | Description: Methamphetamine abstinence will be assessed using both objective and self-reported substance use measures. Measure: * Timeline Followback (TLFB): Self-reported days of methamphetamine use in the past 30 days. |
| Primary | Preliminary efficacy of psilocybin on methamphetamine abstinence | 120 days post drug administration (Follow up #3), visit #11 | Description: Methamphetamine abstinence will be assessed using both objective and self-reported substance use measures. Measure: * Timeline Followback (TLFB): Self-reported days of methamphetamine use in the past 30 days. |
| Primary | Mystical experiences associated with psilocybin administration | Day of drug administration, Visit #6 (on study day 0) | Description: The subjective effects of psilocybin will be assessed using validated self-report questionnaires. Measure: * Mystical Experience Questionnaire (MEQ-30): Total score range = 0-150; higher scores indicate a more intense mystical experience. |
| Primary | Challenging experiences associated with psilocybin administration | Day of drug administration, Visit #6 (on study day 0) | Description: The subjective effects of psilocybin will be assessed using validated self-report questionnaires. Measure: * Challenging Experience Questionnaire (CEQ): Total score range = 0-200; higher scores indicate a more challenging experience. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06899594/registered